PRIMARY STUDY
Clinical and Family Implications of Cannabidiol (CBD)-Dominant Full-Spectrum Phytocannabinoid Extract in Children and Adolescents with Moderate to Severe Non-Syndromic Autism Spectrum Disorder (ASD): An Observational Study on Neurobehavioral Management
Key Findings: Data suggests that full-spectrum CBD-dominant extract [33:1 (CBD: THC)] is a potentially safe and effective option for central and associated signs and symptoms of moderate to severe ASD in children and adolescents (5–18 years old). In addition, treatment may increase the overall quality of life for this patient population and their families.
Type of Study: Clinical Trial
Study Sample Size: 30
Study Result: Positive
Study Location(s): Brazil
Year of Pub: 2024
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC)
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype III
Route of Administration: Oral (Ingestion)
Cannabinoid Ratio: (CBD : THC) 33 : 1 
Dosage Form: The full spectrum oil was provided by Nabix 10.000 (by FarmaUSA) [100 mg/mL of CBD and 3 mg/mL of THC (or 33:1 CBD-THC)]
Dosing Regimen: Starting with 1 mg/kg/day of CBD (0.03 mg/kg/day of THC) Average doses of 3.11 mg/kg/day of CBD (0.09 mg/kg/day of THC)
Starting Dose: 1 mg/kg/day of CBD (0.03 mg/kg/day of THC)
Titration: Individualized and titrated to effects
Treatment Duration: Average treatment duration was 6.6 months
Link to study
